Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from... Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. Mehr anzeigen
WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.12 | 4.93827160494 | 2.43 | 2.57 | 2.31 | 1482698 | 2.48813357 | CS |
| 4 | -0.19 | -6.93430656934 | 2.74 | 3.12 | 2.31 | 1027334 | 2.5901804 | CS |
| 12 | 1.25 | 96.1538461538 | 1.3 | 5.17 | 1.265 | 2840354 | 3.54947465 | CS |
| 26 | 1.12 | 78.3216783217 | 1.43 | 5.17 | 1.12 | 1489976 | 3.20065 | CS |
| 52 | 1.42 | 125.663716814 | 1.13 | 5.17 | 0.9515 | 1237798 | 2.42533347 | CS |
| 156 | -8.03 | -75.8979206049 | 10.58 | 18.9583 | 0.5902 | 1195775 | 4.64380002 | CS |
| 260 | 0.58 | 29.4416243655 | 1.97 | 30.375 | 0.5902 | 1056853 | 7.59505295 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
